Nereshennye voprosy v lechenii khronicheskogo gepatita V


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review is dedicated to the main problems and outstanding issues of the management of patients with chronic hepatitis B. The problem of treatment of chronic hepatitis B is discussed. The issues of patient selection for antiviral therapy, the optimal choice of antiviral drugs, and the problem of resistance to nucleoside analogues are presented. Particular attention is paid to the effectiveness and safety of long-term treatment of chronic hepatitis B by various nucleoside analogues. Criteria for the treatment cessation are discussed.

Full Text

Restricted Access

References

  1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85.
  2. Hoofnagle JH. Therapy of hepatitis B: unresolved issues and remaining challenges. Viral Hepatitis: five decades of progress and promises for the future. AASLD 2010;52-5.
  3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:22 7-42.
  4. Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009;49(Suppl. 1):112-21.
  5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-62.
  6. Perrillo RP, Lai CL, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-94.
  7. Zeuzem S, Gane E, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20.
  8. Wu IC, et al. Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nukleos(t)ide naive patients with chronic hepatitis B: the BELOW study. Hepatology 2011;54:471A.
  9. Lok AS, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t) ide-naive patients with chronic hepatitis B. Gastroenterology 2012;143(3):619-28. e1. doi: 10.1053/j.gastro.2012.05.037. Epub 2012 May 27.
  10. Reijnders JG, Deterding K, et al. Antiviral effect of entecavir in chronic hepatitis B: influtnce of prior exposure to nucleos(t)ide analogues. J Hepatol 2010;52:493-500.
  11. Данные референс-центра по мониторингу за вирусными гепатитами Роспотребнадзора.
  12. Buster EH, et al. Gastroenterology 2009; 137(6):2002-09.
  13. Zoulium F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol 2012;56:112-22.
  14. Zoulium F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009;137:1593-608.
  15. Liaw YF, et al. Hepatology 2011 ;54( 1 ):91-100.
  16. Hosaka T, et al. AASLD 2012, Boston, MA. Poster 357.
  17. Chen YC, et al. EASL 2013 Poster 521.
  18. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49:185-95.
  19. Verhelst D, Monge M, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002;40: 1331-33.
  20. Peyriere H, Reynes J, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004;35: 269-73.
  21. Rodrigues-Novoa S, Alvares E, et al. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010;9:545-59.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies